Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.90
-0.04 (-0.45%)
At close: May 14, 2026, 4:00 PM EDT
8.91
+0.01 (0.11%)
After-hours: May 14, 2026, 4:11 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$989,491
Market Cap
652.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Arvinas | 246 |
| Sutro Biopharma | 137 |
| Kyverna Therapeutics | 130 |
| BridgeBio Oncology Therapeutics | 92 |
| Zevra Therapeutics | 61 |
| Crescent Biopharma | 44 |
| Forte Biosciences | 19 |
CADL News
- 8 hours ago - Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 day ago - Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 13 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - GlobeNewsWire
- 24 days ago - Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 months ago - Candel Therapeutics price target raised to $26 from $22 at Citi - TheFly
- 2 months ago - Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC - TheFly